SG11201908740VA - Sustained release delivery systems comprising traceless linkers - Google Patents
Sustained release delivery systems comprising traceless linkersInfo
- Publication number
- SG11201908740VA SG11201908740VA SG11201908740VA SG11201908740VA SG 11201908740V A SG11201908740V A SG 11201908740VA SG 11201908740V A SG11201908740V A SG 11201908740VA SG 11201908740V A SG11201908740V A SG 11201908740VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cambridge
- novartis
- delivery systems
- avenue
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000012377 drug delivery Methods 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003141 primary amines Chemical class 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003335 secondary amines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit °nolo Him olo Ho Imo Elio ow (10) International Publication Number WO 2018/193408 Al (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 47/61 (2017.01) A61P 27/02 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 47/69 (2017.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: (22) International Filing Date: PCT/IB2018/052740 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/487,888 20 April 2017 (20.04.2017) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: ADAMS, Christopher M.; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). APRIL, Myriam; Novar- tis Institutes for BioMedical Research, Inc., 250 Massa- chusetts Avenue, Cambridge, MA 02139 (US). FAZAL, Tanzina; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). FORSTER, Cornelia Jutta; 8 Nancy Avenue, Pelham, NH 03076 (US). HALL, Edward Charles; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). LEE, Cameron Chuck- Munn; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS (57) : Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762487888P | 2017-04-20 | 2017-04-20 | |
PCT/IB2018/052740 WO2018193408A1 (en) | 2017-04-20 | 2018-04-19 | Sustained release delivery systems comprising traceless linkers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908740VA true SG11201908740VA (en) | 2019-11-28 |
Family
ID=62116508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908740V SG11201908740VA (en) | 2017-04-20 | 2018-04-19 | Sustained release delivery systems comprising traceless linkers |
Country Status (26)
Country | Link |
---|---|
US (3) | US10751417B2 (en) |
EP (1) | EP3612233A1 (en) |
JP (1) | JP7323453B2 (en) |
KR (1) | KR20190137888A (en) |
CN (1) | CN110603060A (en) |
AR (1) | AR111481A1 (en) |
AU (1) | AU2018255933B2 (en) |
BR (1) | BR112019021810A2 (en) |
CA (1) | CA3057590A1 (en) |
CL (1) | CL2019002969A1 (en) |
CO (1) | CO2019011577A2 (en) |
CR (1) | CR20190479A (en) |
CU (1) | CU20190082A7 (en) |
DO (1) | DOP2019000268A (en) |
EA (2) | EA201992484A1 (en) |
EC (1) | ECSP19075134A (en) |
IL (1) | IL269991B2 (en) |
JO (1) | JOP20190245A1 (en) |
MA (1) | MA50260A (en) |
MX (1) | MX2019012447A (en) |
PE (2) | PE20191837A1 (en) |
PH (1) | PH12019502325A1 (en) |
SG (1) | SG11201908740VA (en) |
TW (1) | TW201842935A (en) |
UY (1) | UY37686A (en) |
WO (1) | WO2018193408A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016301282B2 (en) | 2015-08-03 | 2022-03-17 | Children's Medical Center Corporation | Charged ion channel blockers and methods for use |
IL308091A (en) | 2016-09-13 | 2023-12-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
JOP20190245A1 (en) * | 2017-04-20 | 2019-10-15 | Novartis Ag | Sustained release delivery systems comprising traceless linkers |
TW202027794A (en) * | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | Sustained delivery of angiopoetin-like 3 polypeptides |
JP2022527690A (en) | 2019-03-11 | 2022-06-03 | ノシオン セラピューティクス,インコーポレイテッド | Charged ion channel blockers and usage |
MX2021010869A (en) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Ester substituted ion channel blockers and methods for use. |
US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
JP2022525856A (en) | 2019-03-11 | 2022-05-20 | ノシオン セラピューティクス,インコーポレイテッド | Charged ion channel blockers and usage |
WO2020254617A1 (en) * | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
WO2020254607A1 (en) * | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
CA3143279A1 (en) * | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
US11795320B2 (en) * | 2019-09-20 | 2023-10-24 | Bausch + Lomb Ireland Limited | Grafted polymer and use thereof |
US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
JP2023500891A (en) | 2019-11-06 | 2023-01-11 | ノシオン セラピューティクス,インコーポレイテッド | Charged ion channel blockers and methods of use |
CN111110829A (en) * | 2019-12-24 | 2020-05-08 | 浙江大学 | Nanometer defensin gel scaffold and preparation method and application thereof |
AU2021236130A1 (en) | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
CN111285736A (en) * | 2020-04-09 | 2020-06-16 | 郑州先利达化工有限公司 | Pesticide-fertilizer composition containing potassium phosphite, mineral potassium fulvate and polyglutamic acid |
CN114129780B (en) * | 2020-09-03 | 2022-06-28 | 天津大学 | Preparation and application of light-operated nitric oxide releasing composite hydrogel |
WO2023034299A1 (en) * | 2021-08-31 | 2023-03-09 | The Research Foundation For The State University Of New York | Shear-thinning hydrogels and uses thereof |
US20240075001A1 (en) * | 2022-05-24 | 2024-03-07 | Darren Rubin | Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients |
CN115074402B (en) * | 2022-07-20 | 2022-11-18 | 点滴(南京)生物科技有限公司 | Gamma-sodium polyglutamate crosslinked hydrogel synthesized by enzyme method and synthesis method thereof |
CN115947956B (en) * | 2022-10-09 | 2024-03-19 | 西北农林科技大学 | Pickering nanoemulsion based on bacterial cellulose nanocrystalline and application thereof |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3737523A1 (en) | 1987-11-05 | 1989-05-18 | Bayer Ag | USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP0712635B1 (en) | 1994-05-13 | 2003-05-02 | Kuraray Co., Ltd. | Medical polymer gel |
WO1998009987A1 (en) | 1996-09-06 | 1998-03-12 | Biochem Pharma, Inc. | Lactam inhibitors of thrombin |
BRPI9809387B8 (en) | 1997-04-07 | 2021-05-25 | Genentech Inc | humanized anti-human vascular endothelial growth factor antibody and composition comprising it |
CA2346329A1 (en) | 1998-10-09 | 2000-04-20 | Kamal H. Bouhadir | Hydrogels and water soluble polymeric carriers for drug delivery |
JP2004524297A (en) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | Melanocortin receptor agonist |
EP1664091A1 (en) | 2003-09-18 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US9290617B2 (en) | 2005-07-06 | 2016-03-22 | Molly S. Shoichet | Method of biomolecule immobilization on polymers using click-type chemistry |
US20070060658A1 (en) | 2005-08-31 | 2007-03-15 | Diaz David D | Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
ES2529261T3 (en) | 2006-06-09 | 2015-02-18 | Novartis Ag | Insulin-like growth factor stabilized polypeptides |
ITMI20061726A1 (en) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY |
JP2010518099A (en) | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as channel activating protease inhibitors |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
US8053457B2 (en) | 2007-03-29 | 2011-11-08 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
WO2008148839A2 (en) | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
JPWO2009095954A1 (en) | 2008-01-31 | 2011-05-26 | アップサイド株式会社 | DATA INPUT DEVICE, DATA INPUT METHOD, DATA INPUT PROGRAM, AND RECORDING MEDIUM CONTAINING THE SAME |
LT2237799T (en) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Prodrug comprising a self-cleavable linker |
KR101817284B1 (en) | 2008-06-25 | 2018-01-11 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
EP2352730A4 (en) | 2008-11-07 | 2012-04-25 | Lundbeck & Co As H | Biologically active amides |
JO3265B1 (en) | 2008-12-09 | 2018-09-16 | Novartis Ag | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
AU2010215196B2 (en) | 2009-02-21 | 2015-04-16 | Covidien Lp | Crosslinked fibers and method of making same by extrusion |
WO2010099818A1 (en) | 2009-03-03 | 2010-09-10 | Ao Technology Ag | Thermoreversible polysaccharide hydrogel |
WO2010102663A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Piperazine derivatives for use in therapy |
IN2012DN00352A (en) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
WO2011000945A2 (en) | 2009-07-03 | 2011-01-06 | Nensius Research A/S | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns |
US20120191039A1 (en) | 2009-07-31 | 2012-07-26 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
JP5732053B2 (en) | 2009-07-31 | 2015-06-10 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Sustained insulin composition |
WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
WO2011012715A1 (en) * | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
JP5738291B2 (en) | 2009-07-31 | 2015-06-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Prodrugs containing insulin linker conjugates |
WO2011012722A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
CA2776723C (en) | 2009-10-29 | 2018-09-25 | Ascendis Pharma As | Sterilization of biodegradable hydrogels |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
EP3604264A1 (en) | 2010-04-27 | 2020-02-05 | SynAffix B.V. | Fused cyclooctyne compounds |
WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
SG186850A1 (en) | 2010-07-29 | 2013-02-28 | Rigel Pharmaceuticals Inc | Ampk-activating heterocyclic compounds and methods for using the same |
US9388276B2 (en) | 2011-02-25 | 2016-07-12 | University Of Massachusetts | Monomers and polymers for functional polycarbonates and poly(ester-carbonates) and PEG-co-polycarbonate hydrogels |
CZ304072B6 (en) | 2011-04-26 | 2013-09-25 | Contipro Biotech S.R.O. | Amphoteric material based on crosslinked hyaluronic acid, process for its preparation, materials containing active agents enclosed in hyaluronate network, process for their preparation and their use |
JPWO2012165462A1 (en) | 2011-05-31 | 2015-02-23 | 国立大学法人 東京大学 | Hydrogel and method for producing the same |
US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
EP2741738A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
MX358840B (en) | 2011-09-07 | 2018-09-05 | Prolynx Llc | Hydrogels with biodegradable crosslinking. |
EP2753607B1 (en) | 2011-09-09 | 2016-04-13 | Berry And Associates, Inc. | Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides |
SG11201400815TA (en) | 2011-10-12 | 2014-09-26 | Ascendis Pharma Ophthalmology Division As | Prevention and treatment of ocular conditions |
CA2857548A1 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
JP2013116858A (en) | 2011-12-01 | 2013-06-13 | Dainippon Sumitomo Pharma Co Ltd | Therapeutic medicine containing bdnf-like low molecular compound |
RU2014126484A (en) | 2011-12-01 | 2016-02-10 | Ангиочем Инк. | AIMED COMPOUNDS OF LYSOSOMAL ENZYMES |
US20150148525A1 (en) | 2012-05-18 | 2015-05-28 | Medical Research Council | Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase |
SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
MX363462B (en) | 2012-10-11 | 2019-03-25 | Ascendis Pharma As | DIAGNOSIS, PREVENTION and TREATMENT OF DISEASES OF THE JOINT. |
RU2647729C2 (en) | 2012-10-11 | 2018-03-19 | Асцендис Фарма Ас | Hydrocarbon gel-based prodrugs |
WO2014059446A1 (en) | 2012-10-12 | 2014-04-17 | Case Western Reserve University | Biodegradable hydrogel for polynucleotide delivery |
UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
US20150352246A1 (en) | 2013-01-22 | 2015-12-10 | Prolynx Llc | Sealants having controlled degration |
SG11201506025RA (en) * | 2013-02-08 | 2015-08-28 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
MX366978B (en) | 2013-03-15 | 2019-08-01 | Novartis Ag | Antibody drug conjugates. |
WO2014173759A1 (en) | 2013-04-22 | 2014-10-30 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
DK2988732T3 (en) | 2013-04-22 | 2023-06-26 | Ascendis Pharma As | Modified hydrogels |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
CN104292454B (en) | 2013-07-17 | 2017-12-01 | 北京键凯科技股份有限公司 | Polyethylene glycol cyclooctyne derivative |
TW201536814A (en) | 2013-07-25 | 2015-10-01 | Novartis Ag | Synthetic cyclic polypeptides for the treatment of heart failure |
CN105612174A (en) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | Disulfide cyclic polypeptides for the treatment of heart failure |
CN105612173A (en) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | Cyclic APELIN derivatives for the treatment of heart failure |
JP2016172783A (en) | 2013-08-08 | 2016-09-29 | 生化学工業株式会社 | Structure swelling material |
CA2924661A1 (en) | 2013-10-08 | 2015-04-16 | Ascendis Pharma Osteoarthritis Division A/S | Hydrogel-linked il-1ra prodrug |
KR20160075665A (en) | 2013-10-22 | 2016-06-29 | 프로린크스 엘엘시 | Conjugates of somatostatin and its analogs |
US20160296600A1 (en) | 2013-11-11 | 2016-10-13 | Ascendis Pharma Relaxin Division A/S | Relaxin Prodrugs |
EP3110450B1 (en) | 2014-02-26 | 2023-06-07 | University of Massachusetts Medical School | Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof |
CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
WO2016025752A1 (en) | 2014-08-14 | 2016-02-18 | Prolynx Llc | Reagents for thiol conjugation and conjugates formed therefrom |
TWI806150B (en) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
AU2016205968A1 (en) | 2015-01-09 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs |
WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
US11298427B2 (en) | 2015-05-29 | 2022-04-12 | Ascendis Pharma A/S | Prodrugs comprising a pyroglutamate linker |
BR112018010205A2 (en) | 2015-11-20 | 2018-11-21 | Cristal Delivery B V | active targeting nanoparticles |
US20200164083A1 (en) | 2016-03-16 | 2020-05-28 | Prolynx Llc | Extended release conjugates of exenatide analogs |
AU2017295938C1 (en) | 2016-07-13 | 2021-10-07 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
JOP20190245A1 (en) * | 2017-04-20 | 2019-10-15 | Novartis Ag | Sustained release delivery systems comprising traceless linkers |
-
2017
- 2017-06-16 JO JOP/2019/0245A patent/JOP20190245A1/en unknown
-
2018
- 2018-04-19 WO PCT/IB2018/052740 patent/WO2018193408A1/en unknown
- 2018-04-19 EP EP18722730.1A patent/EP3612233A1/en active Pending
- 2018-04-19 US US15/957,474 patent/US10751417B2/en active Active
- 2018-04-19 AR ARP180101000A patent/AR111481A1/en unknown
- 2018-04-19 MA MA050260A patent/MA50260A/en unknown
- 2018-04-19 BR BR112019021810-6A patent/BR112019021810A2/en active Search and Examination
- 2018-04-19 CR CR20190479A patent/CR20190479A/en unknown
- 2018-04-19 CA CA3057590A patent/CA3057590A1/en active Pending
- 2018-04-19 SG SG11201908740V patent/SG11201908740VA/en unknown
- 2018-04-19 EA EA201992484A patent/EA201992484A1/en unknown
- 2018-04-19 EA EA202192099A patent/EA202192099A3/en unknown
- 2018-04-19 TW TW107113326A patent/TW201842935A/en unknown
- 2018-04-19 CN CN201880026014.7A patent/CN110603060A/en active Pending
- 2018-04-19 MX MX2019012447A patent/MX2019012447A/en unknown
- 2018-04-19 CU CU2019000082A patent/CU20190082A7/en unknown
- 2018-04-19 AU AU2018255933A patent/AU2018255933B2/en active Active
- 2018-04-19 PE PE2019002069A patent/PE20191837A1/en unknown
- 2018-04-19 UY UY0001037686A patent/UY37686A/en not_active Application Discontinuation
- 2018-04-19 PE PE2021000630A patent/PE20211281A1/en unknown
- 2018-04-19 JP JP2019556685A patent/JP7323453B2/en active Active
- 2018-04-19 KR KR1020197033766A patent/KR20190137888A/en not_active Application Discontinuation
-
2019
- 2019-10-11 PH PH12019502325A patent/PH12019502325A1/en unknown
- 2019-10-15 IL IL269991A patent/IL269991B2/en unknown
- 2019-10-17 CL CL2019002969A patent/CL2019002969A1/en unknown
- 2019-10-18 CO CO2019011577A patent/CO2019011577A2/en unknown
- 2019-10-18 DO DO2019000268A patent/DOP2019000268A/en unknown
- 2019-10-18 EC ECSENADI201975134A patent/ECSP19075134A/en unknown
-
2020
- 2020-06-15 US US16/901,601 patent/US20200376129A1/en not_active Abandoned
-
2022
- 2022-11-11 US US18/054,767 patent/US20230201353A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
SG11201807472TA (en) | Amanitin conjugates | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201408054RA (en) | Pegylated oxm variants | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents |